Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibitor Therapeutics, Inc.HPPI · Entity 7783 | Director | February 03, 2019 | February 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibitor Therapeutics, Inc.
Report date February 03, 2019 · Filed February 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.08 · Expires 2029-02-03 | Direct | 986,842 |
Reported balance
After 2019-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-03 · Grant · Acquired 986,842 · Balance 986,842 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2019 Filed Feb 6, 2019 00:52 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantCommon Stock Options · Derivative | 986,842 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0000899243-19-002708 · doc4.xml · derivative · entry 1 MAGRAB E. BRENDAN · CIK 0001196062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986,842 Underlying: Common Stock · 986,842 shares Expires 2029-02-03 Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 22:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantCommon Stock | 65,000 | $0.08 | $5,200.00 |
DisclosureSEC source: 0000899243-18-031718 · doc4.xml · nonDerivative · entry 1 MAGRAB E. BRENDAN · CIK 0001196062 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 22:39 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantCommon Stock Options · Derivative | 345,000 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0000899243-18-007628 · doc4.xml · derivative · entry 1 MAGRAB E. BRENDAN · CIK 0001196062 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,000 Underlying: Common Stock · 345,000 shares Expires 2028-03-13 F1 · security: These options were granted subject to the approval of the majority stockholder of the registrant pursuant to an agreement between the majority stockholder and the registrant. In the event that the majority stockholder does not approve the option grant, the options will be canceled. Read SEC document |
| May 04, 2017 Filed Jul 19, 2017 23:41 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantRestricted Stock Units · Derivative | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018593 · doc4.xml · derivative · entry 1 MAGRAB E. BRENDAN · CIK 0001196062 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The RSUs were issued to the reporting person on May 4, 2017, pursuant to a grant under the issuer's 2014 Equity Incentive Plan. The RSUs will vest in full on January 1, 2018, provided that if such vesting date is not during an open trading window, then such RSUs will vest on the first day that thereafter that is during an open trading window. F2 · derivative.expiration_date: The RSUs were issued to the reporting person on May 4, 2017, pursuant to a grant under the issuer's 2014 Equity Incentive Plan. The RSUs will vest in full on January 1, 2018, provided that if such vesting date is not during an open trading window, then such RSUs will vest on the first day that thereafter that is during an open trading window. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.